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Abstract
The vast majority of small molecules known to modulate kinase activity, target the highly conserved ATP-pocket.
Consequently, such ligands are often less specific and in case of inhibitors, this leads to the inhibition of multiple kinases.
Thus, selective modulation of kinase function remains a major hurdle. One of the next great challenges in kinase research is
the identification of ligands which bind to less conserved sites and target the non-catalytic functions of protein kinases.
However, approaches that allow for the unambiguous identification of molecules that bind to these less conserved sites are
few in number. We have previously reported the use of fluorescent labels in kinases (FLiK) to develop direct kinase binding
assays that exclusively detect ligands which stabilize inactive (DFG-out) kinase conformations. Here, we present the
successful application of the FLiK approach to develop a high-throughput binding assay capable of directly monitoring
ligand binding to a remote site within the MAPK insert of p38a mitogen-activated protein kinase (MAPK). Guided by the
crystal structure of an initially identified hit molecule in complex with p38a, we developed a tight binding ligand which may
serve as an ideal starting point for further investigations of the biological function of the MAPK insert in regulating the p38a
signaling pathway.
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Introduction
During the last decade, a plethora of small molecule kinase
modulators have been developed [1]. The majority of these
molecules bind to the highly conserved ATP pocket and are often
plagued by modest selectivity, which in the case of kinase
inhibitors leads to the inhibition of multiple kinases [2,3]. Thus,
selective modulation of kinase function remains a major task and
the identification of next generation ligands which bind to less
conserved sites and specifically target non-catalytic functions of
kinases such as protein-protein interactions, DNA binding and
subcellular localization, are considered the next great challenges in
kinase research [19]. Allosteric ligands that bind to distal binding
sites and often stabilize catalytically inactive kinase conformations
are prime examples of modern kinase inhibitor research and
represent a promising approach towards the development of
selective kinase inhibitors [4]. However, only a few kinases such as
PDK1, Akt, Mek or Bcr-Abl are known to be regulated by such
ligands [1,3,5,6,7] and approaches that allow for the unambiguous
identification of molecules that bind to these less conserved sites
are few in number.
Interestingly, several MAP kinases, cyclin dependant kinases
(CDKs) and glycogen synthase kinase 3 (GSK-3) contain a
hydrophobic pocket at their C terminus about 30 A ˚ away from the
ATP-pocket [8,9]. This C-terminal insert regulates the intracel-
lular localization of GSK-3, binds regulatory proteins in CDK2
and has been shown to bind substrates such as transcription factors
and phosphatases in Erk2 [9]. Recently, Diskin et al. confirmed the
existence of the MAPK insert in p38a using protein X-ray
crystallography and proposed that this structural feature may
‘‘fine-tune’’ kinase activity.[10] This same binding site in p38a is
formed between the a-helices 1L14 and 2L14, and the C-terminal
domain of the kinase (Figure 1A). Structural biology studies of
p38a in complex with b-octyl-glucopyranoside revealed flexibility
of this region and its ability to accommodate small molecules.
Binding of the detergent shifts the two a-helices 1L14 and 2L14
about 3 A ˚ away from the C-lobe and induces a conformational
change of the aEF/aF-loop (Figure 1B) [10]. Although, as yet no
clear biological function can be attributed to this hydrophobic
pocket in p38a, potent ligands which specifically bind to this
allosteric site may offer a valuable starting point for the
development of chemical biology tool compounds for the
investigation of its biological function.
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e39713Figure 1. Crystal structure of p38a and lipid binding FLiK-assay. (A) Crystal structures of wild type p38a (grey) in complex with ATP (red) and
in complex with 1b (green, boxed). The alpha-helix C (blue), activation loop (orange), glycine-rich loop (green) and, MAPK insert (red) are highlighted.
1b binds to the lipid binding site and forms a direct hydrogen bond with Asp294. Furthermore, binding of the ligand is stabilized through a network
of water-mediated hydro-gen bonds as well as p-p-interactions between the quinazoline core and the side chain of Trp197. (B) Conformational
changes triggered by ligand binding to the p38a MAPK insert. Ser252 was mutated to Cys252 and was labeled with a fluorophore (large spheres) to
generate a direct binding assay that detects structural changes in the conformation of the lipid binding site. (C) Acrylodan emission at 475 nm
decreases upon binding of 1b to the lipid binding site of p38a. (D) Endpoint equilibrium measurements can be made to directly obtain the KD of 1b.
doi:10.1371/journal.pone.0039713.g001
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The lipid binding pocket of p38a has been reported to bind
lipids [10] as well as a few small molecule fragments. Interestingly,
these reported ligands do not bind exclusively to the MAPK insert,
as structural studies have revealed secondary binding within the
ATP-pocket [9,11,12]. To our knowledge, no high affinity
compounds are known which exclusively bind to the lipid binding
site of p38a. Thus, identification of new ligands with high affinity
for this pocket might stimulate the development of more specific
ligands which may enable future research to elucidate its function.
To this end, we applied the FLiK approach to develop a
fluorescent-labeled kinase assay system, which specifically takes
advantage of the ligand-induced conformational change of a-
helices 1L14 und 2L14 of the p38a MAPK insert. This HTS-
amenable assay allowed the identification and characterization of
2-phenylquinazolines as ligands for this allosteric site. We were
able to further develop higher affinity ligands and confirmed
binding to this remote pocket using protein X-ray crystallography.
We initially screened a small molecule library using our
previously reported FLiK assay, which detects ligand-induced
conformational changes in the glycine-rich loop of p38a, [13] and
weakly detected binding of the 2-phenylquinazoline 1b to p38a.
To better understand the binding mode and how this ligand
interacts with the glycine-rich loop, we crystallized 1b in complex
with wild type p38a and were surprised to find the molecule
bound exclusively within the p38a MAPK insert (Figure 1A) (PDB
code 4DLI), far away from the glycine-rich loop. The bound
ligand is stabilized by a complex network of interactions. The
primary amine in the 7-position of the quinazoline core directly
hydrogen bonds to the side chain of Asp294. The quinazoline core
itself forms interactions with the peptide backbone of Lys249 and
Ile250 via two mediating water molecules. Furthermore, the side
chain of Trp197 stabilizes binding of the quinazoline core via p-p-
interactions. Interestingly, the side chain of Ser251 forms two
water-mediated hydrogen bonds to the peptide backbone of
Trp197 that may further stabilize the conformation of the aEF/
aF-loop and the flipped orientation of the Trp197 side chain
which is adopted when the ligand is bound. The cyclopropyl
substituent occupies a hydrophobic subpocket that is formed by
the side chains of Leu195, Leu232, Leu236 and Leu291 in the
back of this binding pocket. Finally, the secondary amine which
bridges the cyclopropyl residue to the quinazoline core interacts
with the side chain of Glu192 and the peptide backbone of both
Leu291 and Asp292 via water-mediated hydrogen bonds.
However, in order to accurately measure the affinity of these
compounds and to understand structure-activity relationships, it
was necessary to develop a direct binding assay to enable specific
detection of ligands binding within the MAPK insert. We sought
to take advantage of the flexibility of this site in response to ligand
binding and applied the FLiK approach to this pocket by
introducing a Cys mutation (S252C) via site-directed mutagenesis
into the flexible loop bridging a-helices 1L14 and 2L14, to enable
subsequent labeling of the Cys side chain with the environmen-
tally-sensitive fluorophore acrylodan (Figure 1B). We expected that
conformational changes induced by ligand binding to this site
would change the conformation of the MAP insert and,
consequently, the charged microenvironment in the vicinity of
acrylodan. Indeed, the altered fluorescent properties resulted in a
shift of the emission maxima in the ligand bound state (Figure 1C).
Upon ligand binding to this site, the ratio of fluorescence
intensities measured at these maxima changed in a dose-
dependent manner, allowing direct determination of the binding
constant KD (Figure 1D). Using this assay, the initial hit 1b bound
with a KD of 2.4 mM to the p38a MAPK insert. SB203580 and
BIRB-796, known p38a inhibitors which bind within the ATP
binding site, were not detected up to a concentration of 10 mM
(data not shown) confirming that the observed fluorescence response
is due solely to binding to the p38a MAPK insert.
Guided by the crystal structure of 1b in complex with p38a we
synthesized a focused set of 2-arylquinazolines designed to probe
the MAP insert pocket and increase compound binding affinity
within this site (Figure 2). We hypothesized that this cavity would
tolerate larger and more hydrophobic side chains at the 4-position
of the quinazoline core. Briefly, the quinazoline cores were
generated by a Niementowski-type strategy which entailed
condensing amidines with the appropriate amino carboxylic acids.
Position-4 of the resultant quinazolinols was functionalized
through chlorination using SOCl2, thereby enabling the subse-
quent introduction of primary amines to this position via
nucleophilic substitution. Finally, the nitro groups on the quinazo-
line scaffolds were reduced utilizing Pd/C and ammonium
formate as a hydrogen donor, to afford the corresponding 4,6-
quinazolinediamines. The resulting SAR of this focused set of
ligands followed the predicted trend with 8a being the tightest
binder with a KD of 280 nM (Figure 3). As revealed by protein X-
ray crystallography of the corresponding amine analog 8b (PDB
code 4DLJ), the phenylethylene moiety extends further into the
hydrophobic pocket when compared to 1b, suggesting that the
deeper occupancy of this hydrophobic sub-pocket by the large
substituent in the 4-position likely contributes to the increased
affinity of 8a (Figure 4B). This also explains the slight loss of
potency of 7a and 6a, which have progressively shorter moieties at
this position. Interestingly, all corresponding amine analogs bound
to the lipid binding pocket with lower affinities than their
corresponding nitro analogs. Also, introduction of a pyridine in
the 2-position of the quinazoline core decreased the binding
affinity. Due to the hydrophobic nature of the MAPK insert in
p38a, we speculate that the introduction of polar groups or
heteroatoms might be less tolerated. Although several co-
crystallization attempts were unsuccessful, we postulate that the
nitro-substituent may increase affinity by forming favorable water-
or ion-mediated interactions with Asp residues 292 and 294.
Considering the unique binding mode of 1b, we wanted to better
understand why this compound was initially detected, although
weakly, and initially identified by our glycine-rich loop FLiK
binding assay. We carried out a co-evolution analysis of the
sequences of several mammalian CMGC kinases [14] using the
analysis algorithms previously described by Lockless and Ranga-
nathan [15]. This analysis supports the existence of a network of
interdependent amino acids which link the hydrophobic pocket to
the N-lobe of CMGC kinases, thus providing evidence of a clear
correlation between residues in the ATP pocket of p38a and its
MAPK insert (Figure 4C, D). Interestingly, this analysis is
supported by NMR data recently reported by Francis et al.i n
which the binding of the p38a DFG-out inhibitor BIRB-796 not
only perturbed chemical shifts within the ATP binding site but also
affected the chemical shifts of residues in the MAPK insert in the
C-terminal lobe [16]. While it is important to note that this
analysis merely detects evolutionary correlations, the internal
‘‘hydrophobic spine’’ highlighted by this analysis, and proposed
elsewhere, [17,18] appears to be well in line with our experimental
results.
Discussion
Although initial detection of 1b with a binding assay based on
conformational changes of the glycine-rich loop supports this
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observe any inhibition of kinase activity when testing this focused
library of MAP insert binders on p38a. Additionally, 1b was
profiled against 95 additional kinases in activity-based biochemical
assays (Figure 5). Interestingly, there are naturally occurring
isoforms of p38a which show altered signaling pathway prefer-
ences [19]. The major differences between these isoforms and wild
type p38a lie at the C-terminal end of the kinase, including regions
within or proximal to the MAP kinase insert. We propose that the
MAP kinase insert may have a scaffolding function and somehow
regulates p38a signaling independent of the activity of p38a itself
[20]. Although it is beyond the scope of this work, we believe that
future studies aimed at elucidating the biological function(s) of this
site may rely on the use of tightly binding molecules, such as those
presented, which can perturb the conformation of the MAP kinase
insert, disrupt or enhance protein-protein interactions with this
structural feature and provide kinase researchers with alternative
mechanisms for modulating the complex MAPK network [21,22].
In conclusion, we have developed a fluorescence-based HTS
binding assay for the MAPK insert of p38a and identified scaffolds
which bind exclusively to this unique pocket. Using protein X-ray
crystallography, we validated the screening results and successfully
guided the medicinal chemistry efforts to generate potent binders
of the p38a lipid binding site. These compounds might present a
valuable starting point for further investigations of the p38a
MAPK insert biology. Also, the presented assay is a further proof
of the general applicability of the FLiK technology and presents an
advantageous strategy for the identification of yet unknown kinase
modulators.
Materials and Methods
The fluorophore 6-acryloyl-2-dimethylaminonaphthalene (acry-
lodan) was purchased from Invitrogen GmbH (Germany).
Cuvettes and mini stir bars were obtained from Carl Roth GmbH
(Germany). Small volume (20 mL fill volume) black flat bottom
384-well plates were obtained from Greiner Bio-One GmbH
(Solingen, Germany). Crystallization plates (EasyXtal Tool; 24-
Figure 2. General synthesis of 2-arylquinazolines. See table in Figure 3 for identity of substituents (R).
doi:10.1371/journal.pone.0039713.g002
Figure 3. Structure activity relationship of 2-arylquinazolines.
Each concentration of compound was tested in triplicate. Ratiometric
emission values were plotted against the concentration of compound
on a logarithmic scale to generate a binding curve. KD values of various
2-arylquinazolines were determined bound to p38a.
doi:10.1371/journal.pone.0039713.g003
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for the p38a HTRF assay kit were purchased from CisBio
(Bagnols-sur-Ce `ze, France).
Expression, purification and labeling of p38a
The human p38a kinase construct containing the mutations
required for specific labeling (C119S/C162S/S252C) as well as
wild type p38a were cloned into a pOPINF vector and
transformed as an N-terminal His-tag construct with a PreScission
Protease cleavage site into BL21(DE3) Codon+RIL E. coli. Protein
expression, purification, fluorophore labeling and verification of
mono-labeling of the kinase were performed essentially as
described previously. Labeling of the mutant p38a protein with
thiol-reactive acrylodan was carried out by adding a 1.5:1 molar
excess of the fluorophore (dissolved in DMSO) to the purified
protein in 50 mM Hepes Buffer (pH 7.0). The mixture was
allowed to react in the dark overnight at 4uC. Unreacted
acrylodan was subsequently removed by three cycles of buffer
exchange into FLiK Measurement Buffer (50 mM Hepes Buffer,
pH 7.4+200 mM NaCl) using a 10k-MWCO Centricon. The
protein was concentrated to ,200 mM, aliquoted and frozen at
280uC. Mono-labeling of the protein was verified by ESI-MS as
described previously [23,24].
Characterization of the p38a lipid lite FLiK assay
Characterization of the fluorescence response of MAP insert-
labeled p38a was carried out as described previously for p38a
labeled on the activation loop [23]. For this particular FLiK assay,
we employed 1b as a reference compound since protein X-ray
crystal structures revealed exclusive binding to the lipid binding
site of p38a. The binding of this ligand induces movement in the
MAP insert, thereby altering the microenvironment and the
Figure 4. Co-crystal structure of p38a and co-evolution analysis. (A) Crystal structure of wild type p38a (grey) in complex with 8b (yellow).
(B) Alignment of 1b and 8b bound to the lipid binding site of MAPK p38a. The 2-phenyl quinazoline scaffolds align nicely. The phenyl ethylene
moiety of 8b extends further into the hydro-phobic back pocket (brown) resulting in a higher binding affinity. (C, D) p38a in complex with 1b. Amino
acids showing significant co-evolution are colored according to the strength of the cumulative effect they exert on other residues (C) and of the
cumulative effect other residues have on them (D), yellow symbolizing the strongest effect on both panels.
doi:10.1371/journal.pone.0039713.g004
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containing a suspension of 50 nM acrylodan-labeled p38a in FLiK
Buffer was excited at 386 nm and emission spectra were measured
in the absence and presence of increasing concentrations of 1b.
The compound was dissolved in 100% DMSO and delivered in
sequential small doses to a single sample. The %v/v DMSO did
not exceed 0.2% in cuvettes. These measurements revealed that
the major emission maximum shifts from ,475 nm to ,515 nm
as the lipid acrylodan-labeled lipid binding sites become saturated
with 1b. This shift in emission maxima enabled the use of
ratiometric values (R=I515/I475) for plotting binding curves and
determining the KD of ligands. Ratiometric fluorescence readouts
are advantageous in that they provide an internal correction for
small errors in sample volume which can affect signal intensity. All
measurements of the cuvettes were made with a JASCO FP-6500
fluorescence spectrophotometer (JASCO GmbH, Germany).
Adaptation to high-throughput screening formats
The assay was adapted to high-throughput screening formats
which enabled KD values to be determined in black small volume
assay plates. Briefly, a dilution series of each compound was first
prepared in 100% DMSO at 20X the desired final concentration
and 1 mL was transferred to the assay plate. Compounds were
then mixed with 19 mL of FLiK Buffer (supplemented with 0.01%
Triton X-100) containing acrylodan-labeled p38a (100 nM). The
final concentration of compound in the dilution series ranged from
0–50 mM (5% v/v DMSO final). Plates were covered with an
adhesive aluminum foil and incubated for 30 min at RT prior to
measurement of emission intensities at 470 and 520 nm using a
Tecan Safire
2 plate reader. The adjustment in chosen wavelengths
in 384-well plates was necessary to maximize the resulting
fluorescence ratio as we suspect the addition of detergent to assay
buffer caused a slight shift in the emission maxima. Binding curves
were plotted using the ratio R=I520/I470 to determine the KD.A
calculated Z’.0.7 (using negative and positive binding controls)
suggests that the FLiK assay for the lipid site of p38a is robust and
amenable to high-throughput screening formats.
Chemistry
Unless otherwise noted, all reagents and solvents were
purchased from Acros, Fluka, Sigma, Aldrich or Merck and used
without further purification. Dry solvents were purchased as
anhydrous reagents from commercial suppliers.
1H and
13C NMR
spectra were recorded on a Varian Mercury 400, Bruker Avance
DRX 400, Bruker DRX 500 or Varian Inova 600 spectrometer.
1H NMR spectroscopy chemical shifts are reported in d (ppm) as s
(singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet),
m (multiplet) and bs (broad singlet), and are referenced to the
residual solvent signal: CDCl3 (7.26), CD3OD (4.87) and, DMSO-
d6 (2.50).
13C NMR spectra are referenced to the residual solvent
signal: CDCl3 (77.0), CD3OD (21.4), DMSO-d6 (39.0). All final
compounds were purified to .95% purity, as determined by high-
performance liquid chromatography (HPLC). Purities were
measured using an Agilent 1200 Series HPLC system with UV
detection at 210 nm (System: Agilent Eclipse XDB-C18
4.66150 mm, 5 mM, 10 to 100% CH3CN in H2O, with 0.1%
TFA, for 15 min at 1.0 mL/min). High resolution electrospray
ionization mass spectra (ESI-FTMS) were recorded on a Thermo
LTQ Orbitrap (high resolution mass spectrometer from Thermo
Electron) coupled to an ‘Accela’ HPLC System supplied with a
‘Hypersil GOLD’ column (Thermo Electron). Analytical TLC was
carried out on Merck 60 F245 aluminum-backed silica gel plates.
Compounds were purified by column chromatography using
Baker silica gel (40–70 mm particle size). Preparative HPLC was
conducted on a Varian HPLC system (Pro Star 215) with a VP
250/21 Nucleosil C18 PPN column from Macherey-Nagel and
monitored by UV at l=254 nm. Microwave-assisted reactions
were carried out with a ‘Discover’ system from CEM Corporation.
Synthesis of 7-Nitro-2-phenyl-4(3H)-quinazolinone
4a. Benzamidine 3a (6.0 g, 50 mmol) and 4-nitro-2-aminoben-
zoic acid 2 (2.8 g, 16 mmol) were dissolved in 2-methoxyethanol
(300 mL) after which acetic acid (3.6 mL, 63 mmol) was added.
The solution then heated at reflux (132uC) for 20 h with stirring.
The reaction mixture was then cooled, filtered and the filtrate
washed several times with cold MeOH to afford the desired
product 4a (2.8 g, 65%) as a green-yellow colored solid which was
utilized in other reactions without further purification.
1H-NMR
(400 MHz, DMSO-d6): d 12.90 (s, 1H), 8.42 (d, J=2.2 Hz, 1H),
8.36 (d, J=8.7 Hz, 1H), 8.24–8.19 (m, 3H), 7.66–7.55 (m, 3H);
13C-NMR (101 MHz, DMSO-d6): d 162.29, 155.45, 152.20,
149.93, 132.92, 132.89, 129.59, 129.06, 128.91, 126.14, 123.16,





4a (100 mg, 0.373 mmol) was transferred to a dry flask under
argon after which thionyl chloride (2 mL) and 1–2 drops DMF
were added. The reaction was then heated at reflux (80uC) for 3 h
after which the solvent was removed under vacuum. This afforded
Figure 5. Kinase selectivity profile of 1b. Compound 1b was profiled against a selected panel of 95 different kinases at a concentration of 10 mM
employing a radioactive (
33P-ATP) filter-binding assay (National Centre for Protein Kinase Profiling, Dundee). The numbers represent the remaining
kinase activity in %. The profiling reveals that compound 1b does not inhibit enzymatic activity of any of the tested kinases.
doi:10.1371/journal.pone.0039713.g005
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without any further purification in the following reaction. The
chloride (100 mg, 0.35 mmol) was dissolved in dry DCM (4 mL)
and cyclopropylamine (37 mL, 0.52 mmol) in i-PrOH (2 mL) was
then added drop-wise. The reaction mixture was then stirred at rt
for 24 h, after which the solvent was removed under vacuum. The
resulting residue was subsequently purified by silica gel column
chromatography (3% MeOH/DCM as elution solvent) to afford
the desired product 1a as a yellow solid (89 mg, 83%).
1H-NMR
(400 MHz, DMSO-d6) d 8.69 (d, J=3.6 Hz, 1H), 8.54 (dd,
J=6.6, 3.0 Hz, 2H), 8.44 (dd, J=10.7, 5.7 Hz, 2H), 8.16 (dd,
J=9.0, 2.3 Hz, 1H), 7.56–7.48 (m, 3H), 3.27–3.21 (m, 1H), 0.95–
0.86 (m, 2H), 0.77–0.68 (m, 2H);
13C-NMR (101 MHz, DMSO-
d6) d 161.22, 160.58, 149.94, 149.90, 137.82, 130.72, 128.33,
128.19, 125.23, 122.80, 118.34, 117.33, 24.48, 6.13. HRMS (ESI-




quinazolinamine 6a. The reaction was performed as described
above for 1b, in that the required chloride (100 mg, 0.373 mmol)
in dry DCM (2 mL) was reacted with cyclopropylmethylamine
(44.95 mL, 0.53 mmol) i-PrOH (2 mL) to afford the desired
product 6a as a yellow solid (47.0 mg, 42%) after purification by
silica gel column chromatography (DCM as eluent).
1H-NMR
(400 MHz, DMSO-d6): d 8.88 (br s, 1H), 8.52 (d, J=9.0 Hz, 1H),
8.50–8.45 (m, 2H), 8.43 (d, J=2.4 Hz, 1H), 8.19 (dd, J=9.0, 2.4
Hz, 1H), 7.54–7.51 (m, 3H), 3,57–3.54 (m, 2H), 1.35–1.22 (m,
1H), 0.57–0.48 (m, 2H), 0.40–0.34 (m, 2H);
13C-NMR (101 MHz,
Table 1. Data Collection and Refinement Statistics for p38a crystal structures in complex with 1b and 8b
a.
p38awith 1b (4DLI) p38awith 8b (4DLJ)
Data collection
Space group P212121 P212121
Cell dimensions
a, b, c (A ˚) 66.26, 74.22, 77.92 65.98, 74.51, 78.32
a, b, c (u) 90.00, 90.00, 90.00 90.00, 90.00, 90.00
Resolution (A ˚) 45.0–1.91 (2.00–1.91)
a 45.0–2.60 (2.70–2.60)
a
Rsym or Rmerge (%) 4.0 (40.1) 7.6 (35.9)
I/sI 22.0 (4.0) 17.0 (4.3)
Completeness (%) 99.5 (99.8) 99.8 (99.7)
Redundancy 3.97 (4.03) 4.34 (3.36)
Refinement
Resolution (A ˚) 41.7–1.91 39.2–2.60











Bond lengths (A ˚) 0.015 0.016
Bond angles (u) 1.455 1.551
Data collection details
Wavelength (A ˚) 1.00000 1.54170
Temperature 90K 100K
X-ray source Synchrotron radiation Bruker AXS Microstar
Ramachandran Plot
Residues in most favored regions 87.7% 90.2%
Residues in additional allowed regions 11.7% 8.8%
Residues in generously allowed regions 0.6% 1.0%
Residues in disallowed regions 0.0% 0.0%
aFor all p38a complex structures, diffraction data from one crystal was used to determine the structure. Values in parenthesis are for the highest resolution shell.
doi:10.1371/journal.pone.0039713.t001
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128.42, 128.13, 125.32, 122.64, 118.45, 117.43, 45.50, 10.50,




quinazolinamine 7a. The reaction was performed as described
above with 1b, in that the required chloride (100 mg,
0.373 mmol) in dry DCM (2 mL) was reacted with benzylamine
(57.29 mL, 0.525 mmol) in i-PrOH (2 mL) to afford the desired
product 7a as a yellow solid (104.6 mg, 84%) after silica gel
column chromatography (DCM as elution solvent).
1H-NMR
(400 MHz, DMSO-d6): d 9.39 (br s, 1H), 8.57 (d, J=9.1 Hz, 1H),
8.49–8.44 (m, 3H), 8.24 (dd, J=9.1, 2.3 Hz, 1H), 7.53–7.45 (m,
5H), 7.36–7.32 (m, 2H), 7.26–722 (m, 1H), 4.94 (d, J=5.7 Hz,
2H);
13C-NMR (101 MHz, DMSO-d6): d 161.15, 159.38, 150.19,
137.61, 134.64, 130.87, 129.53, 129.20, 128.45, 128.19, 127.56,
127.03, 125.30, 122.77, 118.73, 117.47, 44.17; HRMS (ESI-MS):




quinazolinamine 8a. The reaction was performed as described
above with 1b, in that the required chloride (100 mg,
0.373 mmol) in dry DCM (2 mL) was reacted with phenethyla-
mine (66.13 mL, 0.525 mmol) in i-PrOH (2 mL) to afford the
desired product 8a as a yellow solid (111.5 mg, 86%) after silica
gel column chromatography (DCM as elution solvent).
1H-NMR
(400 MHz, DMSO-d6): d 8.94 (br s, 1H), 8.52–8.42 (m, 4H), 8.18
(dd, J=9.0, 2.3 Hz, 1H), 7.54–7.52 (m, 3H), 7.34–7.28 (m, 4H),
7.24–7.18 (m, 1H), 3.91–3.85 (m, 2H), 3.06 (t, J=7.5, 2H);
13C-
NMR (101 MHz, DMSO-d6): d 161.03, 159.28, 150.03, 149.53,
139.41, 137.52, 130.89, 128.76, 128.47, 128.42, 128.15, 126.24,
125.18, 122.48, 118.60, 117.38, 42.68, 34.29; HRMS (ESI-MS):






quinazolinamine 1a (32 mg, 0.10 mmol) and ammonium formate
(40 mg, 0.60 mmol) were dissolved in absolute EtOH (3 mL). A
spatula tip of Pd/C (5%) was then added and the reaction mixture
was heated at reflux (90uC) for 2 h. The reaction solution was
cooled and filtered through celite, and the filtrate evaporated
under vacuum. Purification of the resulting residue was performed
by preparative HPLC (Eluent: 0.1% TFA in MECN/H2O) to
afford 1b as a yellow solid (18 mg, 65%).
1H-NMR (400MHz,
DMSO-d6) d 8.48 (dd, J=7.5, 2.0 Hz, 2H), 7.89 (d, J=8.6 Hz,
1H), 7.81 (s, 1H), 7.56–7.42 (m, 3H), 6.83–6.68 (m, 2H), 5.87 (s,
2H), 3.19–3.12 (m, 1H), 0.89–0.76 (m, 2H), 0.70–0.60 (m, 2H);
13C-NMR (101 MHz, CD3OD) d 161.29, 157.35, 156.29, 141.56,
133.29, 131.95, 129.15, 128.63, 125.17, 117.52, 101.94, 97.39,





quinazolinediamine 6b. The reduction was performed as
described above for 1b, utilizing N–(cyclopropylmethyl)–7–nitro-
2–phenyl–4–quinazolinamine 6a (46 mg, 0.14 mmol) and ammo-
nium formate (54.5 mg, 0.864 mmol) to afford compound 6b as a
yellow solid (16 mg, 43%) after silica gel column chromatography
(1.5% MeOH in DCM as eluent).
1H-NMR (400 MHz, DMSO-
d6): d 8.42 (dd, J=8.0, 1.5 Hz, 2H), 7.91 (d, J=8.8 Hz, 1H), 7.87–
7.84 (m, 1H), 7.50–7.39 (m, 3H), 6.76 (dd, J=8.8, 2.2 Hz, 1H),
6.73 (d, J=2.1 Hz, 1H), 5.80 (s, 2H), 3.49 (t, J=6.2 Hz, 2H),
1.28–1.21 (m, 1H), 0.51–0.44 (m, 2H), 0.36–0.30 (m, 2H);
13C-
NMR (101 MHz, DMSO-d6): d 159.21, 159.07, 152.59, 151.83,
139.25, 129.60, 128.07, 127.70, 123.66, 115.44, 106.26, 104.65,





7b. The reduction was performed as described above for 1b,
utilizing N–benzyl–7–nitro-2–phenyl–4–quinazolinamine 7a
(40 mg, 0.11 mmol) and ammonium formate (42.4 mg,
0.67 mmol) in EtOH (8 mL) to afford compound 7b as a yellow
solid (16 mg, 44%) after silica gel column chromatography (1%
MeOH/DCM as eluent).
1H-NMR (400 MHz, DMSO-d6): d
8.40–8.34 (m, 3H), 7.95 (d, J=8.8 Hz, 1H), 7.46–7.39 (m, 5H),
7.32–7.29 (m, 2H), 7.23–7.20 (m, 1H), 6.78 (dd, J=8.8, 2.2 Hz,
1H), 6.74 (d, J=2.1 Hz, 1H), 5.84 (s, 2H), 4.85 (d, J=5.8 Hz,
2H);
13C-NMR (101 MHz, DMSO-d6): d 159.03, 158.97, 152.63,
152.06, 140.48, 139.17, 129.49, 128.17, 127.96, 127.64, 127.32,
126.56, 123.53, 115.55, 106.29, 104.63, 43.50; (ESI-MS): Calcu-




quinazolinediamine 8b. The reduction was performed as
described for 1b above, with 7–nitro-2–phenyl–N–(2–pheny-
lethyl)–4–quinazolinamine 8a (48 mg, 0.12 mmol) and ammoni-
um formate (48.8 mg, 0.77 mmol) in EtOH (8 mL) to afford
compound 8b as a yellow solid (15 mg, 34%) after silica gel
column chromatography (1.5% MeOH in DCM as eluent).
1H-
NMR (400 MHz, DMSO-d6): d 8.46 (dd, J=7.9, 1.5 Hz, 2H),
7.97–7.92 (m, 1H), 7.87 (d, J=8.8 Hz, 1H), 7.52–7.42 (m, 3H),
7.34–7.31 (m, 4H), 7.25–7.18 (m, 1H), 6.79–6.72 (m, 2H), 5.86 (s,
2H), 3.84–3.78 (m, 2H), 3.02 (t, J=7.5 Hz, 2H);
13C-NMR
(101 MHz, DMSO-d6): d 159.10, 159.03, 157.64, 151.82, 139.89,
139.25, 129.64, 128.74, 128.44, 128.10, 127.69, 126.10, 123.57,
115.51, 106.22, 104.68, 42.29, 35.05; HRMS (ESI-MS): Calcu-
lated: 341.17607 for C22H21N4 [M+H]
+, Found: 341.17574.
Synthesis of 7-Nitro-2-(4-pyridinyl)-4(3H)-quinazolinone
4b. Pyridine-4-carboximidamide 14 (1.50 g, 9.5 mmol), 4-nitro-
2-aminobenzoic acid (0.57 g, 3.1 mmol) and acetic acid (0.97 mL,
17 mmol) were dissolved in 2-methoxyethanol (20 mL) and the
solution heated at reflux (132uC) for 20 h with stirring, as
described above for the synthesis of 4a. Work-up as before
afforded the desired product 4b (0.479 g, 57%) as a brown-
colored solid, which was used without further purification.
1H-
NMR (400 MHz, DMSO-d6): d 13.18 (s, 1H), 8.83 (d, J=6.0 Hz,
2H), 8.49 (d, J=2.1 Hz, 1H), 8.40 (d, J=8.7 Hz, 1H), 8.29 (dd,
J=8.7, 2.1 Hz, 1H), 8.14 (d, J=6.1 Hz, 2H);
13C-NMR (101
MHz, DMSO-d6): d 161.24, 152.79, 151.39, 150.14, 149.66,
139.70, 128.30, 125.89, 122.66, 121.91, 120.93; HRMS (ESI-




quinazolinamine 5a. The reaction was performed as described
above for the synthesis of compound 1a, with 7-nitro-2-(4-
pyridinyl)-4(3H)-quinazolinone 4b (300 mg, 1.05 mmol) being
used to generated the respective chloride, after which cyclopro-
pylamine (219 mL, 3.15 mmol) was used with the addition of an
aliquot of NEt3 (218 mL, 1.57 mmol), to afford the desired product
5a as a yellow oil (80 mg, 25%) after column chromatography (1%
MeOH/DCM as eluent).
1H-NMR (400 MHz, DMSO-d6): d
8.82 (br d, J=3.6 Hz, 1H), 8.76 (d, J=5.7 Hz, 2H), 8.50–8.47 (m,
2H), 8.37–8.35 (m, 2H), 8.23 (dd, J=9.0, 2.3 Hz, 1H), 3.29–3.22
(m, 1H), 0.96–0.90 (m, 2H), 0.78–0.73 (m, 2H);
13C-NMR
(101 MHz, DMSO-d6): d 160.83, 159.47, 150.17, 150.05, 149.56,
145.04, 125.32, 122.99, 121.90, 119.23, 117.73, 24.53, 6.07;




quinazolinamine 7c. The reaction was performed as described
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pyridinyl)-4(3H)-quinazolinone 4b (100 mg, 0.373 mmol) used to
generated the respective chloride after which benzylamine
(114.6 mL, 1.05 mmol) to afford the desired product 7c as a
yellow solid (66 mg, 51%) after column chromatography (1%
MeOH/DCM as eluent, followed by a second purification
utilizing 60% EtOAc/petroleum ether as solvent).
1H-NMR
(400 MHz, DMSO-d6): d 9.47 (br t, J=5.7 Hz, 1H), 8.74 (d,
J=5.7 Hz, 2H), 8.60 (d, J=9.0 Hz, 1H), 8.52 (d, J=2.2 Hz, 1H),
8.32–8.27 (m, 3H), 7.48 (d, J=7.4 Hz, 2H), 7.36–7.33 (m, 2H),
7.27–7.24 (m, 1H), 4.95 (d, J=5.5 Hz, 2H);
13C-NMR (101
MHz, DMSO-d6): d 159.57, 159.42, 150.21, 149.81, 144.91,
138.86, 128.39, 127.53, 126.99, 125.33, 123.06, 121.84, 119.50,




quinazolinamine 8c. The reaction was performed as described
above for the synthesis of compound 1a, with 7-nitro-2-(4-
pyridinyl)-4(3H)-quinazolinone 4b (100 mg, 0.373 mmol) used to
generated the respective chloride after which phenylethylamine
(132 mL, 1.05 mmol) was utilized to afford the desired product 8c
as a yellow solid (70 mg, 54%) after column chromatography (1%
MeOH in DCM, followed by a second column using 60% EtOAc:
petroleum ether as solvent).
1H-NMR (400 MHz, DMSO-d6): d
9.01–8.98 (m, 1H), 8.77 (d, J=5.6 Hz, 2H), 8.51–8.48 (m, 2H),
8.33 (d, J=5.4 Hz, 2H), 8.27 (dd, J=9.0, 1.9 Hz, 1H), 7.34–7.28
(m, 4H), 7.22–7.18 (m, 1H), 3.93–3.90 (m, 2H), 3.07 (t, J=7.4 Hz,
2H);
13C-NMR (101 MHz, DMSO-d6): d 159.52, 159.40, 150.13,
149.69, 145.09, 139.30, 128.72, 128.38, 126.17, 125.20, 123.01,
121.85, 119.37, 117.82, 117.76, 42.56, 34.25; HRMS (ESI-MS):





quinazolinediamine 5b. The reduction was performed as
described above for the synthesis of 1b, with N-cyclopropyl-7-
nitro-2-(4-pyridinyl)-4-quinazolinamine 5a (55 mg, 0.179 mmol)
and ammonium formate (67.7 mg, 1.07 mmol) in EtOH (5 mL)
and the reaction mixture being heated at reflux (90uC) for 3 h.
After a similar work-up by filtration, purification was carried out
by preparative HPLC (0.1% TFA in H2O/MeCN). The
combined fractions were concentrated under vacuum and then
made basic with NEt3. This was followed by an extraction of the
aqueous phase with EtOAc (4 times) and subsequent drying of the
organic phase with Na2SO4. After filtration and evaporation of the
solvent under vacuum the desired product 5b was isolated as a
yellow solid (8.0 mg, 16%). 1H-NMR (400 MHz, MeOH-d4): d
8.65 (d, J=4.6 Hz, 2H), 8.39 (d, J=4.6 Hz, 2H), 7.81 (d, J=8.8
Hz, 1H), 6.96–6.85 (m, 2H), 1.15 (br d, J=6.1 Hz, 1H), 0.92–0.89
(m, 2H), 0.73–0.68 (m, 2H);
13C-NMR (101 MHz, MeOH-d4): d
162.58, 159.92, 154.35, 152.96, 150.21, 149.33, 124.51, 124.09,
118.15, 107.77, 107.03, 25.05, 7.16; HRMS (ESI-MS): Calculat-
ed: 278.14002 for C16H16N5 [M+H]
+, Found: 278.14004.
Protein crystallography
Various inhibitors were co-crystallized with wild type p38a
using conditions similar to those described previously [23]. Briefly,
protein-inhibitor complexes were prepared by mixing 40 mL p38a
(10 mg/mL) with 0.4 mL of inhibitor (100 mM in DMSO) and
incubating the mixture for 1 h on ice. Samples were centrifuged at
13,000 rpm for 5 min to remove excess inhibitor. In some cases,
co-crystallization carried out in the presence of excess inhibitor
improved occupancy of the compounds in the crystal structure.
Crystals were grown in 24-well crystallization plates using the
hanging drop vapor diffusion method and by mixing 1.5 mL
protein-inhibitor solution with 0.5 mL reservoir (100 mM MES
pH 5.6–6.2, 20–30% PEG4000 and 50 mM n-octyl-b-D-gluco-
pyranoside). Crystallization plates (EasyXtal Tool; 24-well) were
obtained from Qiagen GmbH (Hilden, Germany). Cuvettes and
mini stir bars were obtained from Carl Roth GmbH (Karlsruhe,
Germany).
Structure determination, refinement and crystallographic
statistics
For the crystals of p38a with inhibitors 20% glycerol was used
as cryo protectant before they were flash frozen in liquid nitrogen.
Diffraction data of the p38a-1b complex crystals was measured at
the PX10SA beam line of the Swiss Light Source (PSI, Villingen,
Switzerland) using a wavelength close to 1 A ˚. Diffraction data of
the p38a-8b complex was collected in-house. Both datasets were
processed with XDS and scaled using XSCALE [25]. Thep38a-
inhibitor complex structures were solved by molecular replace-
ment with PHASER [26] using the published p38a structures
(PDB code: 1ZYJ) [27] or (PDB code: 2EWA) [28] as templates.
The molecules in the asymmetric unit were manually modified
using the program COOT [29]. The model was first refined with
CNS8 using simulated annealing to reduce model bias. The final
refinement was performed with REFMAC5 [30]. Inhibitor
topology files where generated using the Dundee PRODRG2
server [31]. The two refined structures were validated with
PROCHECK [32]. Data collection, structure refinement statistics,
PDB-ID codes and further details for the data collection as well as
Ramachandran plot results are shown in Table 1. PyMOL was
used to produce the figures [33].
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